ଟ୍ରାଲୋକିନୁମାବ

ଟ୍ରାଲୋକିନୁମାବ
	Tralokinumab Fab fragment bound to IL-13. From PDB ଛାଞ୍ଚ:PDB2.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-13
Clinical data
Trade names	Adtralza, Adbry
Synonyms	CAT-354, tralokinumab-ldrm
AHFS/Drugs.com	monograph
data	US DailyMed: Tralokinumab;
Routes of; administration	Subcutaneous
Legal status
Legal status	CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Chemical and physical data
Formula	C6374H9822N1698O2014S44
Molar mass	୧,୪୩,୮୭୫.୨0 g·mol−1
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Tralokinumab

ଟ୍ରାଲୋକିନୁମାବ (ଇଂରାଜୀ ଭାଷାରେ Tralokinumab), ଆଡ୍ରାଲଜା ଏବଂ ଆଡବ୍ରି ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆଟୋପିକ ଡର୍ମାଟାଇଟିସ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ମଧ୍ୟମରୁ ଗୁରୁତର ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯାହା ଚର୍ମରେ ପ୍ରୟୋଗ କରାଯାଉଥିବା ଅନ୍ୟାନ୍ୟ ଔଷଧଦ୍ୱାରା ନିୟନ୍ତ୍ରିତ ହୁଏ ନାହିଁ । ^[୩] ^[୪] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ଯେପରିକି ସାଧାରଣ ଥଣ୍ଡା, ଇଞ୍ଜେକସନ ସ୍ଥାନରେ ପ୍ରତିକ୍ରିୟାଏବଂ ଆଖିରେ ଯନ୍ତ୍ରଣା ଓ ଲାଲ ରଙ୍ଗ ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲାକ୍‌ସିସ ଏବଂ ଆଞ୍ଜିଓଇଡିଡେମା ହୋଇପାରେ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ କ୍ଷତିର କୌଣସି ପ୍ରମାଣ ନଥିବାବେଳେ, ଏପରି ବ୍ୟବହାର ଭଲ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ସାଇଟୋକାଇନ ଇଣ୍ଟରଲିଉକିନ ୧୩ର କାର୍ଯ୍ୟକଳାପକୁ ଅବରୋଧ କରିଥାଏ ।^[୨] ^[୬]

୨୦୨୧ ମସିହାରେ ୟୁରୋପ, ଆମେରିକା ଏବଂ ଯୁକ୍ତରାଜ୍ୟରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଟ୍ରାଲୋକିନୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ^[୨] ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୨ ସୁଦ୍ଧା ଏହାର ୬୦୦ ମିଗ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୧୦୭୦ ପାଉଣ୍ଡ ଥିଲା ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୁଲ୍ୟ ପ୍ରାୟ ୩୩୦୦ ଡଲାର ଅଟେ ।^[୮]

ଆଧାର

↑ "Summary Basis of Decision (SBD) for Adtralza". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Adtralza EPAR". European Medicines Agency (EMA). 20 April 2021. Archived from the original on 29 June 2021. Retrieved 9 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Adtralza 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 5 July 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Adbry- tralokinumab-ldrm injection, solution". DailyMed. Archived from the original on 13 January 2022. Retrieved 13 January 2022.
↑ ^୫.୦ ^୫.୧ "Tralokinumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 23 October 2022.
↑ Kopf M, Bachmann MF, Marsland BJ (September 2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews. Drug Discovery. 9 (9): 703–18. doi:10.1038/nrd2805. PMID 20811382.
↑ "Tralokinumab". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 15 February 2022. Retrieved 23 October 2022.
↑ "Tralokinumab-Ldrm". Goodrx.com. Archived from the original on 23 October 2022. Retrieved 23 October 2022.

[1] "Summary Basis of Decision (SBD) for Adtralza". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

[EPAR2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Adtralza EPAR". European Medicines Agency (EMA). 20 April 2021. Archived from the original on 29 June 2021. Retrieved 9 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[UK2022-3] ୩.୦ ^୩.୧ ^୩.୨ "Adtralza 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 5 July 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Adbry- tralokinumab-ldrm injection, solution". DailyMed. Archived from the original on 13 January 2022. Retrieved 13 January 2022.

[AHFS2022-5] ୫.୦ ^୫.୧ "Tralokinumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 23 October 2022.

[6] Kopf M, Bachmann MF, Marsland BJ (September 2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews. Drug Discovery. 9 (9): 703–18. doi:10.1038/nrd2805. PMID 20811382.

[7] "Tralokinumab". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 15 February 2022. Retrieved 23 October 2022.

[8] "Tralokinumab-Ldrm". Goodrx.com. Archived from the original on 23 October 2022. Retrieved 23 October 2022.

[୧]

[୩]

[୪]

[୨]

[୫]

[୬]

[୭]

[୮]